Stay updated with breaking news from Contract Pharmacies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
US Court of Appeals for the Third Circuit issued a much-anticipated decision in one of the 340B contract pharmacy cases. The decision is a win for drug manufacturers who have sought to restrict access to 340B prices on drugs dispensed through contract pharmacy arrangements.
Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.
We recently hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.
This Viewpoint documents the history, value, and success of the 340B Pricing Program, which is under threat from pharmaceutical corporations’ withdrawal and fro
We recently hosted an informative webinar on the 340B program and how it has changed drastically with the growing list of drug manufacturers restricting access to medications provided by some contract pharmacies. In this webinar, we talked about what is happening, how to identify the impact on your particular 340B program, and how to develop a plan to move forward. Here’s a replay of 340B for Contract Pharmacies – The Good, Bad, and Downright Ugly.